U.S. markets open in 6 hours 12 minutes

Zomedica Corp. (ZOM)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
2.0500+0.1600 (+8.47%)
At close: 4:00PM EST

Zomedica Corp.

100 Phoenix Drive
Suite 180
Ann Arbor, MI 48108
United States
734 369 2555
http://zomedica.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees28

Key Executives

NameTitlePayExercisedYear Born
Dr. Stephanie Laine Morley D.V.M., DVMPres & Chief Medical Officer263.37kN/A1975
Mr. Bruk HerbstChief Commercial OfficerN/AN/A1969
Mr. Robert CohenCEO & DirectorN/AN/A1958
Ms. Ann Marie Cotter CPACFO & Sec.N/AN/A1970
Mr. Michael SchilkVP of SalesN/AN/AN/A
Mr. David EatonVP of MarketingN/AN/AN/A
Dr. William Carpenter MacArthurConsultantN/AN/A1963
Mr. Robert W. DiMarzoConsultantN/AN/A1957
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Corporate Governance

Zomedica Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.